SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '6avo'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1BZF_A_TMQA170_1
(DIHYDROFOLATE
REDUCTASE)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 LEU B 135
ALA B 158
LEU B 154
LEU B   6
PHE B 124
 None
 1.08A 1bzfA-6avoB:
undetectable		 1bzfA-6avoB:
20.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1YAJ_F_BEZF5023_0
(CES1 PROTEIN)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		4 / 6 GLY A 171
SER A  18
LEU A 193
ILE A 159
 None
 0.96A 1yajF-6avoA:
undetectable		 1yajF-6avoA:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z9H_B_IMNB381_1
(MEMBRANE-ASSOCIATED
PROSTAGLANDIN E
SYNTHASE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 12 PRO A 194
SER A  16
ILE A 173
VAL A  13
LEU A  34
 None
 1.46A 1z9hB-6avoA:
undetectable		 1z9hB-6avoA:
14.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z9H_C_IMNC379_1
(MEMBRANE-ASSOCIATED
PROSTAGLANDIN E
SYNTHASE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 12 PRO A 194
SER A  16
ILE A 173
VAL A  13
LEU A  34
 None
 1.45A 1z9hC-6avoA:
undetectable		 1z9hC-6avoA:
14.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_2_BO221405_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.75A 2f162-6avoB:
21.3		 2f162-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_2_BO221405_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.70A 2f162-6avoB:
21.3		 2f162-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_2_BO221405_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
ALA C  28
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.05A 2f162-6avoC:
29.2		 2f162-6avoC:
21.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_2_BO221405_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.64A 2f162-6avoC:
29.2		 2f162-6avoC:
21.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_2_BO221405_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 THR A   1
LYS A  33
SER A  46
GLY A  47
ALA A  49
SER A 168
 None
 0.54A 2f162-6avoA:
25.8		 2f162-6avoA:
24.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_H_BO2H1400_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  27
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.78A 2f16H-6avoB:
22.0
2f16I-6avoB:
20.4		 2f16H-6avoB:
43.40
2f16I-6avoB:
19.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 10 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.64A 2f16K-6avoB:
21.1
2f16L-6avoB:
21.2		 2f16K-6avoB:
20.44
2f16L-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 10 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.67A 2f16K-6avoB:
21.1
2f16L-6avoB:
21.2		 2f16K-6avoB:
20.44
2f16L-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		7 / 10 THR C   1
ALA C  20
ALA C  22
VAL C  31
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.59A 2f16K-6avoC:
24.6
2f16L-6avoC:
24.8		 2f16K-6avoC:
66.25
2f16L-6avoC:
17.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 10 THR A   1
ALA A  22
LYS A  33
GLY A  47
ALA A  49
 None
 0.54A 2f16K-6avoA:
25.1
2f16L-6avoA:
25.6		 2f16K-6avoA:
20.28
2f16L-6avoA:
17.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.75A 2f16N-6avoB:
21.3		 2f16N-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.70A 2f16N-6avoB:
21.3		 2f16N-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
ALA C  28
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.05A 2f16N-6avoC:
29.3		 2f16N-6avoC:
21.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.63A 2f16N-6avoC:
29.3		 2f16N-6avoC:
21.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 THR A   1
LYS A  33
SER A  46
GLY A  47
ALA A  49
SER A 168
 None
 0.53A 2f16N-6avoA:
25.8		 2f16N-6avoA:
24.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_V_BO2V1401_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  27
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.79A 2f16V-6avoB:
22.0
2f16W-6avoB:
20.4		 2f16V-6avoB:
43.40
2f16W-6avoB:
19.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 10 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.63A 2f16Y-6avoB:
12.3
2f16Z-6avoB:
21.1		 2f16Y-6avoB:
20.44
2f16Z-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 10 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.67A 2f16Y-6avoB:
12.3
2f16Z-6avoB:
21.1		 2f16Y-6avoB:
20.44
2f16Z-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		7 / 10 THR C   1
ALA C  20
ALA C  22
VAL C  31
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.60A 2f16Y-6avoC:
19.9
2f16Z-6avoC:
24.5		 2f16Y-6avoC:
66.25
2f16Z-6avoC:
17.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 10 THR A   1
ALA A  22
LYS A  33
GLY A  47
ALA A  49
 None
 0.55A 2f16Y-6avoA:
14.2
2f16Z-6avoA:
25.6		 2f16Y-6avoA:
20.28
2f16Z-6avoA:
17.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2JAP_A_J01A1249_1
(CLAVALDEHYDE
DEHYDROGENASE)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 LEU B 138
ILE B   3
VAL B 159
ALA B 134
LEU B 122
 None
 1.21A 2japA-6avoB:
undetectable		 2japA-6avoB:
15.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2JAP_C_J01C1249_1
(CLAVALDEHYDE
DEHYDROGENASE)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 LEU B 138
ILE B   3
VAL B 159
ALA B 134
LEU B 122
 None
 1.21A 2japC-6avoB:
undetectable		 2japC-6avoB:
15.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2JAP_D_J01D1249_1
(CLAVALDEHYDE
DEHYDROGENASE)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 LEU B 138
ILE B   3
VAL B 159
ALA B 134
LEU B 122
 None
 1.19A 2japD-6avoB:
undetectable		 2japD-6avoB:
15.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2QD4_A_CHDA801_0
(FERROCHELATASE)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens;
Homo
sapiens) 		5 / 12 LEU A  45
LEU A  98
ARG B  84
LEU A  63
VAL A  82
 None
 1.35A 2qd4A-6avoA:
undetectable		 2qd4A-6avoA:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Z0Y_A_SAMA300_0
(PUTATIVE
UNCHARACTERIZED
PROTEIN TTHA0657)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 9 ALA B 158
VAL B 159
GLY B 162
GLY B 165
LEU B 138
LEU B 135
 None
 1.16A 2z0yA-6avoB:
undetectable		 2z0yA-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3FI0_P_TRPP1001_0
(TRYPTOPHANYL-TRNA
SYNTHETASE)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		4 / 7 GLY B 102
GLN B 109
VAL B  76
ILE B  99
 None
 0.93A 3fi0P-6avoB:
undetectable		 3fi0P-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H52_A_486A3_1
(GLUCOCORTICOID
RECEPTOR)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 12 LEU A 115
GLY A 113
GLN A 122
VAL A 111
ILE A   3
 None
 1.21A 3h52A-6avoA:
undetectable		 3h52A-6avoA:
14.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IAZ_A_AINA1202_1
(LACTOTRANSFERRIN)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		3 / 3 GLU C 116
GLY C 118
THR C 119
 None
 0.59A 3iazA-6avoC:
undetectable		 3iazA-6avoC:
13.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAY_A_SAMA1102_0
(STRUCTURAL PROTEIN
VP3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 ILE B 178
GLY B 102
GLY B 101
PRO B 108
ILE B  37
 None
 1.09A 3jayA-6avoB:
undetectable		 3jayA-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_2_BO221405_1
(PROTEASOME COMPONENT
PRE3
PROTEASOME COMPONENT
PUP1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B   1
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.77A 3mg02-6avoB:
21.2
3mg0V-6avoB:
21.1		 3mg02-6avoB:
21.20
3mg0V-6avoB:
43.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_2_BO221405_1
(PROTEASOME COMPONENT
PRE3
PROTEASOME COMPONENT
PUP1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.68A 3mg02-6avoB:
21.2
3mg0V-6avoB:
21.1		 3mg02-6avoB:
21.20
3mg0V-6avoB:
43.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_2_BO221405_1
(PROTEASOME COMPONENT
PRE3
PROTEASOME COMPONENT
PUP1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 12 SER A  46
GLY A  47
ALA A  49
SER A 169
HIS B 114
SER B 118
 None
 0.97A 3mg02-6avoA:
25.7
3mg0V-6avoA:
25.9		 3mg02-6avoA:
24.86
3mg0V-6avoA:
24.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_2_BO221405_1
(PROTEASOME COMPONENT
PRE3
PROTEASOME COMPONENT
PUP1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 12 THR A   1
ALA A  22
SER A  46
ALA A  49
SER A 168
SER B 118
 None
 1.43A 3mg02-6avoA:
25.7
3mg0V-6avoA:
25.9		 3mg02-6avoA:
24.86
3mg0V-6avoA:
24.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_2_BO221405_1
(PROTEASOME COMPONENT
PRE3
PROTEASOME COMPONENT
PUP1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		8 / 12 THR A   1
LYS A  33
SER A  46
GLY A  47
ALA A  49
SER A 168
HIS B 114
SER B 118
 None
 0.60A 3mg02-6avoA:
25.7
3mg0V-6avoA:
25.9		 3mg02-6avoA:
24.86
3mg0V-6avoA:
24.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_2_BO221405_1
(PROTEASOME COMPONENT
PRE3
PROTEASOME COMPONENT
PUP1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
ALA C  28
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.02A 3mg02-6avoC:
29.2
3mg0V-6avoC:
29.3		 3mg02-6avoC:
21.31
3mg0V-6avoC:
17.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_2_BO221405_1
(PROTEASOME COMPONENT
PRE3
PROTEASOME COMPONENT
PUP1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.63A 3mg02-6avoC:
29.2
3mg0V-6avoC:
29.3		 3mg02-6avoC:
21.31
3mg0V-6avoC:
17.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_H_BO2H1400_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
THR B  21
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.72A 3mg0H-6avoB:
22.2
3mg0I-6avoB:
15.9		 3mg0H-6avoB:
43.40
3mg0I-6avoB:
19.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		8 / 11 ALA B  20
THR B  21
ALA B  27
LYS B  33
ALA B  46
GLY B  47
ALA B  49
SER B 129
 None
 0.57A 3mg0K-6avoB:
21.1
3mg0L-6avoB:
21.2		 3mg0K-6avoB:
20.44
3mg0L-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		8 / 11 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
ALA B  46
GLY B  47
SER B 129
 None
 0.61A 3mg0K-6avoB:
21.1
3mg0L-6avoB:
21.2		 3mg0K-6avoB:
20.44
3mg0L-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
ALA C  28
GLY C  47
ALA C  49
SER C 130
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
None
 1.07A 3mg0K-6avoC:
34.3
3mg0L-6avoC:
24.9		 3mg0K-6avoC:
66.25
3mg0L-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		7 / 11 THR C   1
ALA C  20
VAL C  31
LYS C  33
GLY C  47
ALA C  49
SER C 130
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
None
 0.61A 3mg0K-6avoC:
34.3
3mg0L-6avoC:
24.9		 3mg0K-6avoC:
66.25
3mg0L-6avoC:
17.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 11 THR A   1
LYS A  33
GLY A  47
ALA A  49
SER A 129
 None
 0.51A 3mg0K-6avoA:
25.1
3mg0L-6avoA:
25.8		 3mg0K-6avoA:
20.28
3mg0L-6avoA:
17.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.76A 3mg0N-6avoB:
21.3		 3mg0N-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.69A 3mg0N-6avoB:
21.3		 3mg0N-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
ALA C  28
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.03A 3mg0N-6avoC:
29.3		 3mg0N-6avoC:
21.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.62A 3mg0N-6avoC:
29.3		 3mg0N-6avoC:
21.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 THR A   1
LYS A  33
SER A  46
GLY A  47
ALA A  49
SER A 168
 None
 0.59A 3mg0N-6avoA:
25.7		 3mg0N-6avoA:
24.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_V_BO2V1401_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  27
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.81A 3mg0V-6avoB:
22.1
3mg0W-6avoB:
20.4		 3mg0V-6avoB:
43.40
3mg0W-6avoB:
19.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3SMT_A_ACTA500_0
(HISTONE-LYSINE
N-METHYLTRANSFERASE
SETD3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		3 / 3 PHE A  31
SER A  35
GLN A  53
 None
 0.96A 3smtA-6avoA:
undetectable		 3smtA-6avoA:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_A_1KXA277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 10 ILE B  37
VAL B 100
TYR B 111
TYR B  42
ILE B 178
 None
 1.27A 3uprA-6avoB:
undetectable		 3uprA-6avoB:
13.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UPR_C_1KXC277_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 10 ILE B  37
VAL B 100
TYR B 111
TYR B  42
ILE B 178
 None
 1.28A 3uprC-6avoB:
undetectable		 3uprC-6avoB:
13.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VRJ_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN
10-MER PEPTIDE)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 ILE B  37
VAL B 100
TYR B 111
TYR B  42
ILE B 178
 None
 1.26A 3vrjA-6avoB:
undetectable
3vrjC-6avoB:
undetectable		 3vrjA-6avoB:
13.04
3vrjC-6avoB:
6.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4E1G_A_LNLA701_2
(PROSTAGLANDIN G/H
SYNTHASE 2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		4 / 5 ARG C  19
VAL C 192
LEU C 196
SER C 193
 None
 1.38A 4e1gA-6avoC:
undetectable		 4e1gA-6avoC:
8.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		4 / 7 ASP C 167
SER C 130
SER C  21
ARG C  19
 None
None
BZ7  C 301 (-4.9A)
None
 1.24A 4lv9A-6avoC:
undetectable
4lv9B-6avoC:
undetectable		 4lv9A-6avoC:
11.13
4lv9B-6avoC:
11.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		4 / 7 ASP A 166
SER A 129
SER A  21
ARG A  19
 None
 1.23A 4lv9A-6avoA:
undetectable
4lv9B-6avoA:
undetectable		 4lv9A-6avoA:
9.89
4lv9B-6avoA:
9.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4PGH_D_SAMD401_0
(CAFFEIC ACID
O-METHYLTRANSFERASE)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 12 GLY A 130
LEU A 161
ASP A 157
PHE A 154
ILE A 126
 None
 1.04A 4pghD-6avoA:
undetectable		 4pghD-6avoA:
undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.56A 4qvlV-6avoB:
22.0
4qvlb-6avoB:
21.3		 4qvlV-6avoB:
43.40
4qvlb-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVL_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.60A 4qvlK-6avoB:
21.3
4qvlL-6avoB:
21.2		 4qvlK-6avoB:
20.44
4qvlL-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVL_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.66A 4qvlK-6avoB:
21.3
4qvlL-6avoB:
21.2		 4qvlK-6avoB:
20.44
4qvlL-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVL_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 11 THR A   1
LYS A  33
GLY A  47
ALA A  49
SER B 118
 None
 0.67A 4qvlK-6avoA:
25.1
4qvlL-6avoA:
25.6		 4qvlK-6avoA:
20.28
4qvlL-6avoA:
17.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.58A 4qvlK-6avoC:
34.2
4qvlL-6avoC:
24.8		 4qvlK-6avoC:
66.25
4qvlL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.55A 4qvlH-6avoB:
22.0
4qvlN-6avoB:
21.3		 4qvlH-6avoB:
43.40
4qvlN-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVL_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.60A 4qvlY-6avoB:
12.5
4qvlZ-6avoB:
21.1		 4qvlY-6avoB:
20.44
4qvlZ-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVL_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.66A 4qvlY-6avoB:
12.5
4qvlZ-6avoB:
21.1		 4qvlY-6avoB:
20.44
4qvlZ-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVL_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 11 THR A   1
LYS A  33
GLY A  47
ALA A  49
SER B 118
 None
 0.70A 4qvlY-6avoA:
14.1
4qvlZ-6avoA:
25.6		 4qvlY-6avoA:
20.28
4qvlZ-6avoA:
17.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.59A 4qvlY-6avoC:
19.9
4qvlZ-6avoC:
24.6		 4qvlY-6avoC:
66.25
4qvlZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.54A 4qvmV-6avoB:
21.7
4qvmb-6avoB:
21.3		 4qvmV-6avoB:
43.40
4qvmb-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVM_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 9 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.57A 4qvmK-6avoB:
21.2
4qvmL-6avoB:
21.1		 4qvmK-6avoB:
20.44
4qvmL-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVM_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 9 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.66A 4qvmK-6avoB:
21.2
4qvmL-6avoB:
21.1		 4qvmK-6avoB:
20.44
4qvmL-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.50A 4qvmK-6avoC:
34.2
4qvmL-6avoC:
24.8		 4qvmK-6avoC:
65.00
4qvmL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.53A 4qvmH-6avoB:
22.0
4qvmN-6avoB:
21.2		 4qvmH-6avoB:
43.40
4qvmN-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVM_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 10 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.57A 4qvmY-6avoB:
12.4
4qvmZ-6avoB:
20.8		 4qvmY-6avoB:
20.44
4qvmZ-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVM_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 10 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.66A 4qvmY-6avoB:
12.4
4qvmZ-6avoB:
20.8		 4qvmY-6avoB:
20.44
4qvmZ-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVM_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 10 THR A   1
LYS A  33
GLY A  47
ALA A  49
SER B 118
 None
 0.70A 4qvmY-6avoA:
14.1
4qvmZ-6avoA:
25.4		 4qvmY-6avoA:
20.28
4qvmZ-6avoA:
17.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.50A 4qvmY-6avoC:
25.8
4qvmZ-6avoC:
24.5		 4qvmY-6avoC:
65.00
4qvmZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B   1
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.75A 4qvnV-6avoB:
21.8
4qvnb-6avoB:
21.3		 4qvnV-6avoB:
43.40
4qvnb-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.67A 4qvnV-6avoB:
21.8
4qvnb-6avoB:
21.3		 4qvnV-6avoB:
43.40
4qvnb-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 12 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.56A 4qvnV-6avoB:
21.8
4qvnb-6avoB:
21.3		 4qvnV-6avoB:
43.40
4qvnb-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
CYH B  31
LYS B  33
GLY B  47
ALA B  49
 None
 1.04A 4qvnH-6avoB:
22.0
4qvnI-6avoB:
18.1		 4qvnH-6avoB:
43.40
4qvnI-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 9 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.60A 4qvnK-6avoB:
21.3
4qvnL-6avoB:
21.3		 4qvnK-6avoB:
20.44
4qvnL-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 9 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.65A 4qvnK-6avoB:
21.3
4qvnL-6avoB:
21.3		 4qvnK-6avoB:
20.44
4qvnL-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
ALA C  28
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.12A 4qvnK-6avoC:
34.5
4qvnL-6avoC:
24.8		 4qvnK-6avoC:
65.00
4qvnL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.50A 4qvnK-6avoC:
34.5
4qvnL-6avoC:
24.8		 4qvnK-6avoC:
65.00
4qvnL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B   1
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.75A 4qvnH-6avoB:
22.0
4qvnN-6avoB:
21.2		 4qvnH-6avoB:
43.40
4qvnN-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.67A 4qvnH-6avoB:
22.0
4qvnN-6avoB:
21.2		 4qvnH-6avoB:
43.40
4qvnN-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 12 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.55A 4qvnH-6avoB:
22.0
4qvnN-6avoB:
21.2		 4qvnH-6avoB:
43.40
4qvnN-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 9 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.72A 4qvnY-6avoB:
12.5
4qvnZ-6avoB:
21.2		 4qvnY-6avoB:
20.44
4qvnZ-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
ALA C  28
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.12A 4qvnY-6avoC:
20.0
4qvnZ-6avoC:
24.6		 4qvnY-6avoC:
65.00
4qvnZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.50A 4qvnY-6avoC:
20.0
4qvnZ-6avoC:
24.6		 4qvnY-6avoC:
65.00
4qvnZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.53A 4qvpV-6avoB:
21.7
4qvpb-6avoB:
21.3		 4qvpV-6avoB:
43.40
4qvpb-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 12 THR B   1
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.92A 4qvpH-6avoB:
22.0
4qvpI-6avoB:
18.7		 4qvpH-6avoB:
43.40
4qvpI-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVP_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 10 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.67A 4qvpK-6avoB:
21.2
4qvpL-6avoB:
21.0		 4qvpK-6avoB:
20.44
4qvpL-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.49A 4qvpK-6avoC:
34.3
4qvpL-6avoC:
24.5		 4qvpK-6avoC:
65.00
4qvpL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.51A 4qvpH-6avoB:
22.0
4qvpN-6avoB:
21.3		 4qvpH-6avoB:
43.40
4qvpN-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 12 THR B   1
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.92A 4qvpV-6avoB:
21.9
4qvpW-6avoB:
20.4		 4qvpV-6avoB:
43.40
4qvpW-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVP_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 10 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.67A 4qvpY-6avoB:
12.4
4qvpZ-6avoB:
21.1		 4qvpY-6avoB:
20.44
4qvpZ-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.49A 4qvpY-6avoC:
26.0
4qvpZ-6avoC:
24.6		 4qvpY-6avoC:
65.00
4qvpZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.54A 4qvqV-6avoB:
21.7
4qvqb-6avoB:
21.3		 4qvqV-6avoB:
43.40
4qvqb-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
CYH B  31
LYS B  33
GLY B  47
ALA B  49
 None
 0.99A 4qvqH-6avoB:
22.0
4qvqI-6avoB:
17.9		 4qvqH-6avoB:
43.40
4qvqI-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVQ_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 9 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.71A 4qvqK-6avoB:
21.2
4qvqL-6avoB:
21.2		 4qvqK-6avoB:
20.44
4qvqL-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
ALA C  28
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.11A 4qvqK-6avoC:
34.3
4qvqL-6avoC:
24.8		 4qvqK-6avoC:
65.00
4qvqL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.51A 4qvqK-6avoC:
34.3
4qvqL-6avoC:
24.8		 4qvqK-6avoC:
65.00
4qvqL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.53A 4qvqH-6avoB:
22.0
4qvqN-6avoB:
21.3		 4qvqH-6avoB:
43.40
4qvqN-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
CYH B  31
LYS B  33
GLY B  47
ALA B  49
 None
 1.00A 4qvqV-6avoB:
21.8
4qvqW-6avoB:
20.4		 4qvqV-6avoB:
43.40
4qvqW-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVQ_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 9 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.70A 4qvqY-6avoB:
12.5
4qvqZ-6avoB:
21.0		 4qvqY-6avoB:
20.44
4qvqZ-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
ALA C  28
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.11A 4qvqY-6avoC:
19.9
4qvqZ-6avoC:
24.5		 4qvqY-6avoC:
65.00
4qvqZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.51A 4qvqY-6avoC:
19.9
4qvqZ-6avoC:
24.5		 4qvqY-6avoC:
65.00
4qvqZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVV_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 10 HIS B 114
SER B 118
THR A   1
LYS A  33
ALA A  49
 None
 0.57A 4qvvV-6avoB:
21.7
4qvvb-6avoB:
21.4		 4qvvV-6avoB:
43.40
4qvvb-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVV_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 11 THR B   1
THR B  21
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.87A 4qvvH-6avoB:
22.0		 4qvvH-6avoB:
43.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVV_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		4 / 8 THR B   1
THR B  21
LYS B  33
GLY B  47
 None
 0.70A 4qvvK-6avoB:
21.3
4qvvL-6avoB:
21.0		 4qvvK-6avoB:
20.44
4qvvL-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVV_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		4 / 8 THR C   1
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 0.53A 4qvvK-6avoC:
33.9
4qvvL-6avoC:
24.8		 4qvvK-6avoC:
65.00
4qvvL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVV_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 10 HIS B 114
SER B 118
THR A   1
LYS A  33
ALA A  49
 None
 0.57A 4qvvH-6avoB:
22.0
4qvvN-6avoB:
21.3		 4qvvH-6avoB:
43.40
4qvvN-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVV_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 11 THR B   1
THR B  21
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.87A 4qvvV-6avoB:
22.0		 4qvvV-6avoB:
43.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVV_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		4 / 8 THR B   1
THR B  21
LYS B  33
GLY B  47
 None
 0.69A 4qvvY-6avoB:
12.4
4qvvZ-6avoB:
20.9		 4qvvY-6avoB:
20.44
4qvvZ-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVV_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		4 / 8 THR C   1
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 0.52A 4qvvY-6avoC:
19.6
4qvvZ-6avoC:
24.5		 4qvvY-6avoC:
65.00
4qvvZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.57A 4qvwV-6avoB:
22.0
4qvwb-6avoB:
21.3		 4qvwV-6avoB:
43.40
4qvwb-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVW_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.66A 4qvwK-6avoB:
21.4
4qvwL-6avoB:
21.2		 4qvwK-6avoB:
20.44
4qvwL-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 0.60A 4qvwK-6avoC:
34.2
4qvwL-6avoC:
24.8		 4qvwK-6avoC:
65.00
4qvwL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.57A 4qvwH-6avoB:
22.0
4qvwN-6avoB:
21.3		 4qvwH-6avoB:
43.40
4qvwN-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVW_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.66A 4qvwY-6avoB:
12.5
4qvwZ-6avoB:
21.0		 4qvwY-6avoB:
20.44
4qvwZ-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 0.61A 4qvwY-6avoC:
19.8
4qvwZ-6avoC:
24.6		 4qvwY-6avoC:
65.00
4qvwZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
SER A  46
ALA A  49
 None
 0.62A 4qvyV-6avoB:
21.8
4qvyb-6avoB:
21.3		 4qvyV-6avoB:
43.40
4qvyb-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 11 THR B   1
THR B  21
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.87A 4qvyH-6avoB:
22.0		 4qvyH-6avoB:
43.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVY_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 10 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
 None
 0.56A 4qvyK-6avoB:
21.4
4qvyL-6avoB:
21.2		 4qvyK-6avoB:
20.44
4qvyL-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 ALA C  20
ALA C  22
VAL C  31
LYS C  33
GLY C  47
 BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
 1.03A 4qvyK-6avoC:
33.9
4qvyL-6avoC:
24.8		 4qvyK-6avoC:
65.00
4qvyL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
ALA C  20
ALA C  22
VAL C  31
LYS C  33
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
 0.60A 4qvyK-6avoC:
33.9
4qvyL-6avoC:
24.8		 4qvyK-6avoC:
65.00
4qvyL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
SER A  46
ALA A  49
 None
 0.61A 4qvyH-6avoB:
22.0
4qvyN-6avoB:
21.3		 4qvyH-6avoB:
43.40
4qvyN-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 12 THR B   1
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.90A 4qvyV-6avoB:
22.0
4qvyW-6avoB:
20.4		 4qvyV-6avoB:
43.40
4qvyW-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVY_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 10 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
 None
 0.55A 4qvyY-6avoB:
12.5
4qvyZ-6avoB:
21.1		 4qvyY-6avoB:
20.44
4qvyZ-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 ALA C  20
ALA C  22
VAL C  31
LYS C  33
GLY C  47
 BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
 1.03A 4qvyY-6avoC:
25.6
4qvyZ-6avoC:
24.5		 4qvyY-6avoC:
65.00
4qvyZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
ALA C  20
ALA C  22
VAL C  31
LYS C  33
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
 0.61A 4qvyY-6avoC:
25.6
4qvyZ-6avoC:
24.5		 4qvyY-6avoC:
65.00
4qvyZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW0_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.57A 4qw0V-6avoB:
21.7
4qw0b-6avoB:
21.3		 4qw0V-6avoB:
43.40
4qw0b-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW0_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.65A 4qw0H-6avoB:
22.0
4qw0I-6avoB:
18.6		 4qw0H-6avoB:
43.40
4qw0I-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW0_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		4 / 7 THR B   1
ALA B  20
THR B  21
LYS B  33
 None
 0.60A 4qw0K-6avoB:
21.3		 4qw0K-6avoB:
20.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW0_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 7 THR C   1
ALA C  20
ALA C  22
LYS C  33
MET C  45
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
 0.63A 4qw0K-6avoC:
33.7		 4qw0K-6avoC:
63.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW0_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.55A 4qw0H-6avoB:
22.0
4qw0N-6avoB:
21.3		 4qw0H-6avoB:
43.40
4qw0N-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW0_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.65A 4qw0V-6avoB:
22.0
4qw0W-6avoB:
20.3		 4qw0V-6avoB:
43.40
4qw0W-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW0_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		4 / 7 THR B   1
ALA B  20
THR B  21
LYS B  33
 None
 0.60A 4qw0Y-6avoB:
12.4		 4qw0Y-6avoB:
20.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW0_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 7 THR C   1
ALA C  20
ALA C  22
LYS C  33
MET C  45
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
 0.63A 4qw0Y-6avoC:
19.5		 4qw0Y-6avoC:
63.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.59A 4qw1V-6avoB:
21.7
4qw1b-6avoB:
21.4		 4qw1V-6avoB:
43.40
4qw1b-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 12 THR B   1
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.94A 4qw1H-6avoB:
22.0
4qw1I-6avoB:
18.7		 4qw1H-6avoB:
43.40
4qw1I-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW1_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 11 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.68A 4qw1K-6avoB:
21.3
4qw1L-6avoB:
21.2		 4qw1K-6avoB:
20.44
4qw1L-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW1_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 11 THR A   1
LYS A  33
GLY A  47
ALA A  49
SER B 118
 None
 0.66A 4qw1K-6avoA:
25.1
4qw1L-6avoA:
25.5		 4qw1K-6avoA:
20.28
4qw1L-6avoA:
17.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.54A 4qw1K-6avoC:
34.3
4qw1L-6avoC:
24.9		 4qw1K-6avoC:
65.00
4qw1L-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.59A 4qw1H-6avoB:
22.0
4qw1N-6avoB:
21.4		 4qw1H-6avoB:
43.40
4qw1N-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 12 THR B   1
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.93A 4qw1V-6avoB:
22.0
4qw1W-6avoB:
20.4		 4qw1V-6avoB:
43.40
4qw1W-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW1_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 10 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.69A 4qw1Y-6avoB:
12.4
4qw1Z-6avoB:
21.1		 4qw1Y-6avoB:
20.44
4qw1Z-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.55A 4qw1Y-6avoC:
19.9
4qw1Z-6avoC:
24.6		 4qw1Y-6avoC:
65.00
4qw1Z-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.54A 4qw3V-6avoB:
21.9
4qw3b-6avoB:
21.3		 4qw3V-6avoB:
43.40
4qw3b-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW3_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 10 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.56A 4qw3K-6avoB:
21.1
4qw3L-6avoB:
20.9		 4qw3K-6avoB:
20.44
4qw3L-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW3_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 10 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.66A 4qw3K-6avoB:
21.1
4qw3L-6avoB:
20.9		 4qw3K-6avoB:
20.44
4qw3L-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
ALA C  28
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.23A 4qw3K-6avoC:
33.9
4qw3L-6avoC:
24.7		 4qw3K-6avoC:
65.00
4qw3L-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.58A 4qw3K-6avoC:
33.9
4qw3L-6avoC:
24.7		 4qw3K-6avoC:
65.00
4qw3L-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.54A 4qw3H-6avoB:
21.9
4qw3N-6avoB:
21.3		 4qw3H-6avoB:
43.40
4qw3N-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
CYH B  31
LYS B  33
ALA B  46
ALA B  49
 None
 0.96A 4qw3V-6avoB:
21.8
4qw3W-6avoB:
20.2		 4qw3V-6avoB:
43.40
4qw3W-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW3_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 10 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.56A 4qw3Y-6avoB:
12.3
4qw3Z-6avoB:
20.8		 4qw3Y-6avoB:
20.44
4qw3Z-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW3_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 10 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.65A 4qw3Y-6avoB:
12.3
4qw3Z-6avoB:
20.8		 4qw3Y-6avoB:
20.44
4qw3Z-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
ALA C  28
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.23A 4qw3Y-6avoC:
19.7
4qw3Z-6avoC:
24.4		 4qw3Y-6avoC:
65.00
4qw3Z-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.58A 4qw3Y-6avoC:
19.7
4qw3Z-6avoC:
24.4		 4qw3Y-6avoC:
65.00
4qw3Z-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.55A 4qwuV-6avoB:
22.0
4qwub-6avoB:
21.3		 4qwuV-6avoB:
43.40
4qwub-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
CYH B  31
LYS B  33
GLY B  47
ALA B  49
 None
 1.02A 4qwuH-6avoB:
22.0
4qwuI-6avoB:
18.1		 4qwuH-6avoB:
43.40
4qwuI-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QWU_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 9 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.55A 4qwuK-6avoB:
20.7
4qwuL-6avoB:
21.0		 4qwuK-6avoB:
20.44
4qwuL-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
ALA C  28
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 1.06A 4qwuK-6avoC:
33.3
4qwuL-6avoC:
24.6		 4qwuK-6avoC:
65.00
4qwuL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 0.54A 4qwuK-6avoC:
33.3
4qwuL-6avoC:
24.6		 4qwuK-6avoC:
65.00
4qwuL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.54A 4qwuH-6avoB:
22.0
4qwuN-6avoB:
21.3		 4qwuH-6avoB:
43.40
4qwuN-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
CYH B  31
LYS B  33
GLY B  47
ALA B  49
 None
 1.02A 4qwuV-6avoB:
21.8
4qwuW-6avoB:
20.5		 4qwuV-6avoB:
43.40
4qwuW-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QWU_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 9 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.58A 4qwuY-6avoB:
12.4
4qwuZ-6avoB:
21.2		 4qwuY-6avoB:
20.44
4qwuZ-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
ALA C  28
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 1.08A 4qwuY-6avoC:
19.6
4qwuZ-6avoC:
24.7		 4qwuY-6avoC:
65.00
4qwuZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 0.53A 4qwuY-6avoC:
19.6
4qwuZ-6avoC:
24.7		 4qwuY-6avoC:
65.00
4qwuZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.56A 5bxnV-6avoB:
21.9
5bxnb-6avoB:
21.4		 5bxnV-6avoB:
43.40
5bxnb-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.69A 5bxnH-6avoB:
21.1
5bxnI-6avoB:
18.1		 5bxnH-6avoB:
43.40
5bxnI-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BXN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.59A 5bxnK-6avoB:
21.3
5bxnL-6avoB:
21.1		 5bxnK-6avoB:
20.44
5bxnL-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BXN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.64A 5bxnK-6avoB:
21.3
5bxnL-6avoB:
21.1		 5bxnK-6avoB:
20.44
5bxnL-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BXN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 11 THR A   1
LYS A  33
GLY A  47
ALA A  49
SER B 118
 None
 0.64A 5bxnK-6avoA:
25.1
5bxnL-6avoA:
25.3		 5bxnK-6avoA:
20.28
5bxnL-6avoA:
17.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.60A 5bxnK-6avoC:
34.4
5bxnL-6avoC:
24.5		 5bxnK-6avoC:
66.25
5bxnL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.56A 5bxnH-6avoB:
21.6
5bxnN-6avoB:
21.4		 5bxnH-6avoB:
43.40
5bxnN-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
THR B  21
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.72A 5bxnV-6avoB:
22.2
5bxnW-6avoB:
20.5		 5bxnV-6avoB:
43.40
5bxnW-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BXN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.59A 5bxnY-6avoB:
12.5
5bxnZ-6avoB:
21.1		 5bxnY-6avoB:
20.44
5bxnZ-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BXN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.64A 5bxnY-6avoB:
12.5
5bxnZ-6avoB:
21.1		 5bxnY-6avoB:
20.44
5bxnZ-6avoB:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BXN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 11 THR A   1
LYS A  33
GLY A  47
ALA A  49
SER B 118
 None
 0.67A 5bxnY-6avoA:
14.1
5bxnZ-6avoA:
25.6		 5bxnY-6avoA:
20.28
5bxnZ-6avoA:
17.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.61A 5bxnY-6avoC:
20.0
5bxnZ-6avoC:
24.5		 5bxnY-6avoC:
66.25
5bxnZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5CZ7_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
CYH B  31
LYS B  33
ALA B  46
ALA B  49
 None
 1.00A 5cz7H-6avoB:
22.1
5cz7I-6avoB:
19.3		 5cz7H-6avoB:
43.40
5cz7I-6avoB:
19.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5CZ7_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.56A 5cz7H-6avoB:
22.1
5cz7N-6avoB:
21.3		 5cz7H-6avoB:
43.40
5cz7N-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5CZ7_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 12 THR B   1
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.91A 5cz7V-6avoB:
22.0
5cz7W-6avoB:
20.4		 5cz7V-6avoB:
43.40
5cz7W-6avoB:
19.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5D0X_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.55A 5d0xV-6avoB:
21.8
5d0xb-6avoB:
21.3		 5d0xV-6avoB:
43.40
5d0xb-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5D0X_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 12 THR B   1
THR B  21
CYH B  31
LYS B  33
ALA B  46
ALA B  49
 None
 0.93A 5d0xH-6avoB:
21.9
5d0xI-6avoB:
17.8		 5d0xH-6avoB:
43.40
5d0xI-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5D0X_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 9 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.57A 5d0xK-6avoB:
21.3
5d0xL-6avoB:
21.1		 5d0xK-6avoB:
19.89
5d0xL-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5D0X_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.53A 5d0xH-6avoB:
22.0
5d0xN-6avoB:
21.3		 5d0xH-6avoB:
43.40
5d0xN-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5D0X_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 11 THR B   1
THR B  21
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.88A 5d0xV-6avoB:
21.8		 5d0xV-6avoB:
43.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5D0X_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 9 ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.58A 5d0xY-6avoB:
12.4
5d0xZ-6avoB:
20.9		 5d0xY-6avoB:
19.89
5d0xZ-6avoB:
18.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5F_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
SER A  46
ALA A  49
 None
 0.63A 5l5fV-6avoB:
21.8
5l5fb-6avoB:
21.3		 5l5fV-6avoB:
43.40
5l5fb-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5F_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 12 THR B   1
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.82A 5l5fH-6avoB:
22.1
5l5fI-6avoB:
18.7		 5l5fH-6avoB:
43.40
5l5fI-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5F_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 9 THR A   1
SER A  21
LYS A  33
ALA A  49
SER B 118
 None
 0.69A 5l5fK-6avoA:
25.3
5l5fL-6avoA:
25.2		 5l5fK-6avoA:
20.38
5l5fL-6avoA:
17.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5F_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 9 THR C   1
SER C  21
SER C  27
VAL C  31
MET C  45
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-4.9A)
BZ7  C 301 (-3.4A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-2.8A)
 0.75A 5l5fK-6avoC:
34.5
5l5fL-6avoC:
24.5		 5l5fK-6avoC:
100.00
5l5fL-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5F_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 9 THR C   1
SER C  21
VAL C  31
LYS C  33
MET C  45
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-4.9A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-2.8A)
 0.66A 5l5fK-6avoC:
34.5
5l5fL-6avoC:
24.5		 5l5fK-6avoC:
100.00
5l5fL-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5F_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
SER A  46
ALA A  49
 None
 0.62A 5l5fH-6avoB:
22.1
5l5fN-6avoB:
21.3		 5l5fH-6avoB:
43.40
5l5fN-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5F_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 12 THR B   1
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.81A 5l5fV-6avoB:
21.9
5l5fW-6avoB:
20.5		 5l5fV-6avoB:
43.40
5l5fW-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5F_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 8 THR A   1
SER A  21
LYS A  33
ALA A  49
SER B 118
 None
 0.69A 5l5fY-6avoA:
25.3
5l5fZ-6avoA:
25.5		 5l5fY-6avoA:
20.38
5l5fZ-6avoA:
17.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5F_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		4 / 8 THR A   1
SER A  21
LYS A  33
SER B 120
 None
 0.95A 5l5fY-6avoA:
25.3
5l5fZ-6avoA:
25.5		 5l5fY-6avoA:
20.38
5l5fZ-6avoA:
17.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5F_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 8 THR C   1
SER C  21
LYS C  33
MET C  45
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-4.9A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-2.8A)
 0.59A 5l5fY-6avoC:
34.5
5l5fZ-6avoC:
24.6		 5l5fY-6avoC:
100.00
5l5fZ-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5F_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 8 THR C   1
SER C  21
SER C  27
MET C  45
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-4.9A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-2.8A)
 0.69A 5l5fY-6avoC:
34.5
5l5fZ-6avoC:
24.6		 5l5fY-6avoC:
100.00
5l5fZ-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		7 / 12 HIS B 114
SER B 118
THR A   1
LYS A  33
SER A  46
GLY A  47
ALA A  49
 None
 0.59A 5l5zV-6avoB:
21.0
5l5zb-6avoB:
21.3		 5l5zV-6avoB:
43.40
5l5zb-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5Z_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.62A 5l5zV-6avoC:
29.4
5l5zb-6avoC:
29.3		 5l5zV-6avoC:
17.24
5l5zb-6avoC:
21.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 12 THR B   1
THR B  21
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.92A 5l5zH-6avoB:
22.0
5l5zI-6avoB:
18.8		 5l5zH-6avoB:
43.40
5l5zI-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5Z_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 9 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.71A 5l5zK-6avoB:
21.6
5l5zL-6avoB:
21.1		 5l5zK-6avoB:
19.44
5l5zL-6avoB:
18.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 9 THR C   1
ALA C  20
ALA C  22
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.65A 5l5zK-6avoC:
34.4
5l5zL-6avoC:
24.5		 5l5zK-6avoC:
75.00
5l5zL-6avoC:
14.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5Z_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 9 THR A   1
ALA A  22
LYS A  33
GLY A  47
ALA A  49
 None
 0.54A 5l5zK-6avoA:
25.3
5l5zL-6avoA:
25.2		 5l5zK-6avoA:
19.91
5l5zL-6avoA:
17.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		7 / 12 HIS B 114
SER B 118
THR A   1
LYS A  33
SER A  46
GLY A  47
ALA A  49
 None
 0.58A 5l5zH-6avoB:
22.0
5l5zN-6avoB:
21.3		 5l5zH-6avoB:
43.40
5l5zN-6avoB:
21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5Z_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.62A 5l5zH-6avoC:
27.5
5l5zN-6avoC:
29.3		 5l5zH-6avoC:
17.24
5l5zN-6avoC:
21.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 12 THR B   1
THR B  21
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.91A 5l5zV-6avoB:
22.0
5l5zW-6avoB:
20.3		 5l5zV-6avoB:
43.40
5l5zW-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5Z_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 9 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.72A 5l5zY-6avoB:
21.6
5l5zZ-6avoB:
21.2		 5l5zY-6avoB:
19.44
5l5zZ-6avoB:
18.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 9 THR C   1
ALA C  20
ALA C  22
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.66A 5l5zY-6avoC:
34.4
5l5zZ-6avoC:
24.6		 5l5zY-6avoC:
75.00
5l5zZ-6avoC:
14.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5Z_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 9 THR A   1
ALA A  22
LYS A  33
GLY A  47
ALA A  49
 None
 0.55A 5l5zY-6avoA:
25.3
5l5zZ-6avoA:
25.5		 5l5zY-6avoA:
19.91
5l5zZ-6avoA:
17.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 11 THR B   1
THR B  21
LYS B  33
GLY B  47
ALA B  49
 None
 0.75A 5l66V-6avoB:
21.8
5l66b-6avoB:
21.3		 5l66V-6avoB:
43.40
5l66b-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.52A 5l66V-6avoB:
21.8
5l66b-6avoB:
21.3		 5l66V-6avoB:
43.40
5l66b-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 12 THR B   1
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.91A 5l66H-6avoB:
22.1
5l66I-6avoB:
18.8		 5l66H-6avoB:
43.40
5l66I-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L66_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 10 THR B   1
ALA B  20
THR B  21
LYS B  33
GLY B  47
ALA B  49
 None
 0.71A 5l66K-6avoB:
21.7
5l66L-6avoB:
21.3		 5l66K-6avoB:
19.44
5l66L-6avoB:
18.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L66_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 10 THR A   1
LYS A  33
GLY A  47
ALA A  49
SER B 118
 None
 0.59A 5l66K-6avoA:
25.3
5l66L-6avoA:
25.5		 5l66K-6avoA:
18.96
5l66L-6avoA:
17.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.55A 5l66K-6avoC:
34.7
5l66L-6avoC:
24.8		 5l66K-6avoC:
95.00
5l66L-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
SER C  27
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.60A 5l66K-6avoC:
34.7
5l66L-6avoC:
24.8		 5l66K-6avoC:
95.00
5l66L-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 11 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.51A 5l66H-6avoB:
21.9
5l66N-6avoB:
21.3		 5l66H-6avoB:
43.40
5l66N-6avoB:
21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 12 THR B   1
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.91A 5l66V-6avoB:
21.9
5l66W-6avoB:
20.5		 5l66V-6avoB:
43.40
5l66W-6avoB:
19.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L66_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 10 THR B   1
ALA B  20
THR B  21
LYS B  33
GLY B  47
ALA B  49
 None
 0.71A 5l66Y-6avoB:
21.7
5l66Z-6avoB:
21.2		 5l66Y-6avoB:
19.44
5l66Z-6avoB:
18.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L66_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 10 THR A   1
LYS A  33
GLY A  47
ALA A  49
SER B 118
 None
 0.60A 5l66Y-6avoA:
25.3
5l66Z-6avoA:
25.6		 5l66Y-6avoA:
18.96
5l66Z-6avoA:
17.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.54A 5l66Y-6avoC:
34.7
5l66Z-6avoC:
24.6		 5l66Y-6avoC:
95.00
5l66Z-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
SER C  27
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.61A 5l66Y-6avoC:
34.7
5l66Z-6avoC:
24.6		 5l66Y-6avoC:
95.00
5l66Z-6avoC:
14.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_B_BO2B305_1
(PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.64A 5lf3b-6avoC:
28.8		 5lf3b-6avoC:
20.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_B_BO2B305_1
(PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 12 THR A   1
LYS A  33
SER A  46
GLY A  47
ALA A  49
SER A 168
 None
 0.61A 5lf3b-6avoA:
26.1		 5lf3b-6avoA:
26.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_H_BO2H306_1
(PROTEASOME SUBUNIT
BETA TYPE-7
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 10 THR B   1
ALA B  20
THR B  21
CYH B  31
ALA B  46
GLY B  47
ALA B  49
 None
 0.83A 5lf3H-6avoB:
22.0
5lf3I-6avoB:
20.9		 5lf3H-6avoB:
44.44
5lf3I-6avoB:
18.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_K_BO2K305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  20
THR B  21
LYS B  33
GLY B  47
ALA B  49
 None
 0.67A 5lf3K-6avoB:
21.8
5lf3L-6avoB:
20.1		 5lf3K-6avoB:
17.73
5lf3L-6avoB:
18.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_K_BO2K305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B 193
THR B 160
ALA B 161
GLY B 171
GLY B 170
ASP B 166
 None
 1.42A 5lf3K-6avoB:
21.8
5lf3L-6avoB:
20.1		 5lf3K-6avoB:
17.73
5lf3L-6avoB:
18.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_K_BO2K305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		8 / 11 THR C   1
ALA C  20
ALA C  22
LYS C  33
MET C  45
GLY C  47
ALA C  49
TYR C 169
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
None
 0.75A 5lf3K-6avoC:
35.4
5lf3L-6avoC:
25.9		 5lf3K-6avoC:
75.00
5lf3L-6avoC:
15.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_K_BO2K305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 11 THR A   1
ALA A  22
LYS A  33
GLY A  47
ALA A  49
 None
 0.53A 5lf3K-6avoA:
25.5
5lf3L-6avoA:
27.1		 5lf3K-6avoA:
19.61
5lf3L-6avoA:
15.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_N_BO2N304_1
(PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.64A 5lf3N-6avoC:
28.8		 5lf3N-6avoC:
20.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_N_BO2N304_1
(PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		6 / 12 THR A   1
LYS A  33
SER A  46
GLY A  47
ALA A  49
SER A 168
 None
 0.61A 5lf3N-6avoA:
26.1		 5lf3N-6avoA:
26.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_V_BO2V303_1
(PROTEASOME SUBUNIT
BETA TYPE-7
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 10 THR B   1
ALA B  20
THR B  21
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.63A 5lf3V-6avoB:
22.0
5lf3W-6avoB:
20.9		 5lf3V-6avoB:
44.44
5lf3W-6avoB:
18.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_V_BO2V303_1
(PROTEASOME SUBUNIT
BETA TYPE-7
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.44A 5lf3V-6avoC:
30.1
5lf3W-6avoC:
26.6		 5lf3V-6avoC:
16.24
5lf3W-6avoC:
15.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_Y_BO2Y305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  20
THR B  21
LYS B  33
GLY B  47
ALA B  49
 None
 0.68A 5lf3Y-6avoB:
21.8
5lf3Z-6avoB:
20.0		 5lf3Y-6avoB:
17.73
5lf3Z-6avoB:
18.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_Y_BO2Y305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B 193
THR B 160
ALA B 161
GLY B 171
GLY B 170
ASP B 166
 None
 1.41A 5lf3Y-6avoB:
21.8
5lf3Z-6avoB:
20.0		 5lf3Y-6avoB:
17.73
5lf3Z-6avoB:
18.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_Y_BO2Y305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		8 / 11 THR C   1
ALA C  20
ALA C  22
LYS C  33
MET C  45
GLY C  47
ALA C  49
TYR C 169
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
None
 0.74A 5lf3Y-6avoC:
35.4
5lf3Z-6avoC:
25.8		 5lf3Y-6avoC:
75.00
5lf3Z-6avoC:
15.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_Y_BO2Y305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 11 THR A   1
ALA A  22
LYS A  33
GLY A  47
ALA A  49
 None
 0.54A 5lf3Y-6avoA:
25.6
5lf3Z-6avoA:
27.1		 5lf3Y-6avoA:
19.61
5lf3Z-6avoA:
15.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_B_6V8B304_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B   1
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.75A 5lf7V-6avoB:
22.0
5lf7b-6avoB:
21.5		 5lf7V-6avoB:
undetectable
5lf7b-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_B_6V8B304_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.70A 5lf7V-6avoB:
22.0
5lf7b-6avoB:
21.5		 5lf7V-6avoB:
undetectable
5lf7b-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_B_6V8B304_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
ALA C  28
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.02A 5lf7V-6avoC:
30.1
5lf7b-6avoC:
28.8		 5lf7V-6avoC:
undetectable
5lf7b-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_B_6V8B304_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.68A 5lf7V-6avoC:
30.1
5lf7b-6avoC:
28.8		 5lf7V-6avoC:
undetectable
5lf7b-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_B_6V8B304_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 12 THR A   1
LYS A  33
SER A  46
GLY A  47
ALA A  49
 None
 0.64A 5lf7V-6avoA:
26.5
5lf7b-6avoA:
26.2		 5lf7V-6avoA:
undetectable
5lf7b-6avoA:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_H_6V8H305_0
(PROTEASOME SUBUNIT
BETA TYPE-3
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 11 THR B   1
ALA B  20
THR B  21
CYH B  31
ALA B  46
GLY B  47
ALA B  49
 None
 0.76A 5lf7H-6avoB:
22.0
5lf7I-6avoB:
20.9		 5lf7H-6avoB:
undetectable
5lf7I-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_K_6V8K305_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  20
THR B  21
LYS B  33
GLY B  47
ALA B  49
 None
 0.69A 5lf7K-6avoB:
21.8
5lf7L-6avoB:
20.0		 5lf7K-6avoB:
undetectable
5lf7L-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_K_6V8K305_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B 193
THR B 160
ALA B 161
GLY B 171
GLY B 170
ASP B 166
 None
 1.47A 5lf7K-6avoB:
21.8
5lf7L-6avoB:
20.0		 5lf7K-6avoB:
undetectable
5lf7L-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_K_6V8K305_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 ALA C  20
ALA C  22
VAL C  31
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 1.10A 5lf7K-6avoC:
35.4
5lf7L-6avoC:
25.9		 5lf7K-6avoC:
undetectable
5lf7L-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_K_6V8K305_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		8 / 11 THR C   1
ALA C  20
ALA C  22
VAL C  31
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.68A 5lf7K-6avoC:
35.4
5lf7L-6avoC:
25.9		 5lf7K-6avoC:
undetectable
5lf7L-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_K_6V8K305_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 11 THR A   1
ALA A  22
LYS A  33
GLY A  47
ALA A  49
 None
 0.57A 5lf7K-6avoA:
25.6
5lf7L-6avoA:
27.1		 5lf7K-6avoA:
undetectable
5lf7L-6avoA:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_N_6V8N305_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B   1
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.74A 5lf7H-6avoB:
22.0
5lf7N-6avoB:
21.6		 5lf7H-6avoB:
undetectable
5lf7N-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_N_6V8N305_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.69A 5lf7H-6avoB:
22.0
5lf7N-6avoB:
21.6		 5lf7H-6avoB:
undetectable
5lf7N-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_N_6V8N305_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
ALA C  28
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.02A 5lf7H-6avoC:
30.2
5lf7N-6avoC:
28.8		 5lf7H-6avoC:
undetectable
5lf7N-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_N_6V8N305_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.67A 5lf7H-6avoC:
30.2
5lf7N-6avoC:
28.8		 5lf7H-6avoC:
undetectable
5lf7N-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_N_6V8N305_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 12 THR A   1
LYS A  33
SER A  46
GLY A  47
ALA A  49
 None
 0.63A 5lf7H-6avoA:
26.6
5lf7N-6avoA:
26.2		 5lf7H-6avoA:
undetectable
5lf7N-6avoA:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_V_6V8V303_0
(PROTEASOME SUBUNIT
BETA TYPE-3
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 11 THR B   1
ALA B  20
THR B  21
CYH B  31
ALA B  46
GLY B  47
ALA B  49
 None
 0.75A 5lf7V-6avoB:
22.0
5lf7W-6avoB:
21.0		 5lf7V-6avoB:
undetectable
5lf7W-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_Y_6V8Y306_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B   1
ALA B  20
THR B  21
LYS B  33
GLY B  47
ALA B  49
 None
 0.68A 5lf7Y-6avoB:
21.8
5lf7Z-6avoB:
20.0		 5lf7Y-6avoB:
undetectable
5lf7Z-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_Y_6V8Y306_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B 193
THR B 160
ALA B 161
GLY B 171
GLY B 170
ASP B 166
 None
 1.45A 5lf7Y-6avoB:
21.8
5lf7Z-6avoB:
20.0		 5lf7Y-6avoB:
undetectable
5lf7Z-6avoB:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_Y_6V8Y306_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 ALA C  20
ALA C  22
VAL C  31
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 1.07A 5lf7Y-6avoC:
35.5
5lf7Z-6avoC:
25.9		 5lf7Y-6avoC:
undetectable
5lf7Z-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_Y_6V8Y306_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		8 / 11 THR C   1
ALA C  20
ALA C  22
VAL C  31
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.66A 5lf7Y-6avoC:
35.5
5lf7Z-6avoC:
25.9		 5lf7Y-6avoC:
undetectable
5lf7Z-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_Y_6V8Y306_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 11 THR A   1
ALA A  22
LYS A  33
GLY A  47
ALA A  49
 None
 0.57A 5lf7Y-6avoA:
25.7
5lf7Z-6avoA:
27.1		 5lf7Y-6avoA:
undetectable
5lf7Z-6avoA:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_A_1KXA301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 10 ILE B  37
VAL B 100
TYR B 111
TYR B  42
ILE B 178
 None
 1.28A 5u98A-6avoB:
undetectable		 5u98A-6avoB:
13.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5U98_D_1KXD301_1
(HLA CLASS I
HISTOCOMPATIBILITY
ANTIGEN, B-57 ALPHA
CHAIN)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 10 ILE B  37
VAL B 100
TYR B 111
TYR B  42
ILE B 178
 None
 1.27A 5u98D-6avoB:
undetectable		 5u98D-6avoB:
13.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_B_BO2B201_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B   1
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.72A 6hwdV-6avoB:
21.8
6hwdb-6avoB:
21.4		 6hwdV-6avoB:
52.50
6hwdb-6avoB:
33.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_B_BO2B201_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.62A 6hwdV-6avoB:
21.8
6hwdb-6avoB:
21.4		 6hwdV-6avoB:
52.50
6hwdb-6avoB:
33.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_B_BO2B201_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens;
Homo
sapiens) 		6 / 12 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.56A 6hwdV-6avoB:
21.8
6hwdb-6avoB:
21.4		 6hwdV-6avoB:
52.50
6hwdb-6avoB:
33.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_H_BO2H301_0
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 12 THR B   1
ALA B  27
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.87A 6hwdH-6avoB:
22.1
6hwdI-6avoB:
18.8		 6hwdH-6avoB:
52.50
6hwdI-6avoB:
25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 11 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.70A 6hwdK-6avoB:
21.0
6hwdL-6avoB:
21.3		 6hwdK-6avoB:
32.50
6hwdL-6avoB:
22.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B 193
THR B 160
ALA B 161
GLY B 171
GLY B 170
ASP B 166
 None
 1.47A 6hwdK-6avoB:
21.0
6hwdL-6avoB:
21.3		 6hwdK-6avoB:
32.50
6hwdL-6avoB:
22.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		7 / 11 THR C   1
ALA C  20
ALA C  22
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.64A 6hwdK-6avoC:
34.6
6hwdL-6avoC:
24.9		 6hwdK-6avoC:
66.25
6hwdL-6avoC:
21.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
ALA C  28
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.21A 6hwdK-6avoC:
34.6
6hwdL-6avoC:
24.9		 6hwdK-6avoC:
66.25
6hwdL-6avoC:
21.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 11 THR A   1
ALA A  22
LYS A  33
GLY A  47
ALA A  49
 None
 0.55A 6hwdK-6avoA:
25.2
6hwdL-6avoA:
25.8		 6hwdK-6avoA:
31.25
6hwdL-6avoA:
23.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_N_BO2N201_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B   1
THR B  21
ALA B  27
LYS B  33
GLY B  47
 None
 0.72A 6hwdH-6avoB:
22.1
6hwdN-6avoB:
21.3		 6hwdH-6avoB:
52.50
6hwdN-6avoB:
33.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_N_BO2N201_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		5 / 12 THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.64A 6hwdH-6avoB:
22.1
6hwdN-6avoB:
21.3		 6hwdH-6avoB:
52.50
6hwdN-6avoB:
33.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_N_BO2N201_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens;
Homo
sapiens) 		6 / 12 HIS B 114
SER B 118
THR A   1
LYS A  33
GLY A  47
ALA A  49
 None
 0.55A 6hwdH-6avoB:
22.1
6hwdN-6avoB:
21.3		 6hwdH-6avoB:
52.50
6hwdN-6avoB:
33.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_V_BO2V301_0
(PROTEASOME SUBUNIT
BETA TYPE-2)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 11 THR B   1
ALA B  27
CYH B  31
LYS B  33
ALA B  46
GLY B  47
ALA B  49
 None
 0.87A 6hwdV-6avoB:
21.9		 6hwdV-6avoB:
52.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		7 / 11 THR B   1
ALA B  20
THR B  21
ALA B  27
LYS B  33
GLY B  47
ALA B  49
 None
 0.71A 6hwdY-6avoB:
16.5
6hwdZ-6avoB:
21.3		 6hwdY-6avoB:
32.50
6hwdZ-6avoB:
22.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-10
(Homo
sapiens) 		6 / 11 THR B 193
THR B 160
ALA B 161
GLY B 171
GLY B 170
ASP B 166
 None
 1.47A 6hwdY-6avoB:
16.5
6hwdZ-6avoB:
21.3		 6hwdY-6avoB:
32.50
6hwdZ-6avoB:
22.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		7 / 11 THR C   1
ALA C  20
ALA C  22
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.63A 6hwdY-6avoC:
20.2
6hwdZ-6avoC:
24.6		 6hwdY-6avoC:
66.25
6hwdZ-6avoC:
21.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
ALA C  28
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.21A 6hwdY-6avoC:
20.2
6hwdZ-6avoC:
24.6		 6hwdY-6avoC:
66.25
6hwdZ-6avoC:
21.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-9
(Homo
sapiens) 		5 / 11 THR A   1
ALA A  22
LYS A  33
GLY A  47
ALA A  49
 None
 0.56A 6hwdY-6avoA:
18.6
6hwdZ-6avoA:
26.0		 6hwdY-6avoA:
31.25
6hwdZ-6avoA:
23.17